Eli Lilly’s Obesity Drugs Are Printing Money, But the Black Market Is Printing Retatrutide

The Obesity Cash Machine

Mounjaro, Lilly’s diabetes-turned-weight-loss phenom, raked in $10.7 billion in Q3, up 65% year-over-year, while Zepbound—its sibling drug specifically for obesity—pulled in $5.4 billion, up 49% [1]. Together, they accounted for two-thirds of Lilly’s revenue, proving that the global appetite for GLP-1 drugs isn’t just strong—it’s ravenous. Even Medicare’s pilot program covering obesity meds has already funneled half a million seniors to Lilly’s drugs since July [3].

But here’s the twist: Lilly’s realized prices dropped 15% overall, with Zepbound taking the biggest hit. The company is selling more vials than ever, but at lower margins, a trade-off that’s starting to look like the new normal. CFO Lucas Montarces shrugged it off on the earnings call, noting that volume growth (up 53%) is 'more than offsetting' price declines [1]. Translation: Lilly’s strategy is to flood the zone and let economies of scale do the rest.

The Pipeline: Retatrutide vs. the Dark Web

While Mounjaro and Zepbound dominate, Lilly’s next-gen weight-loss drug, retatrutide, is stealing headlines for all the wrong reasons. The triple-hormone agonist (targeting GLP-1, GIP, and glucagon) just crushed Ozempic in a Phase 3 diabetes trial, with patients losing 20% of their body weight versus Ozempic’s 9% [4]. But the drug is already being sold illegally online, with Lilly issuing public warnings and begging payment processors to crack down on rogue vendors [5].

Meanwhile, Lilly’s oral obesity pill, Foundayo, is struggling to gain traction, with Q3 sales of $184 million missing estimates by 20% [6]. Analysts blame slow adoption and competition from Novo Nordisk’s rival pill—proof that even Lilly can’t win every round in the obesity wars.

Acquisitions and the 'Everything Else' Portfolio

Lilly isn’t putting all its eggs in the obesity basket. The company dropped $4.2 billion on acquisitions in Q3 alone, snapping up AtaiBeckley (psychedelics for depression) and Merida Biosciences (autoimmune therapies) [1]. Its oncology and immunology drugs, like Jaypirca and Omvoh, are growing at triple-digit rates, albeit from a small base. The goal? To turn 'Lilly' into more than a synonym for 'weight-loss juggernaut.'

Still, the math is unforgiving: Mounjaro and Zepbound are growing so fast that even doubling sales in other divisions barely moves the needle. Case in point: Lilly’s 'other key products' revenue jumped 100% in Q3—to $17.1 billion. That’s not a niche; that’s a rounding error [1].

What to Watch Next

1. **Retatrutide’s FDA timeline**: Phase 3 data is in, but approval isn’t expected until 2027. Can Lilly keep the black market at bay until then?

2. **Medicare’s obesity pilot**: The program expires in 2027, and its future is uncertain. If coverage lapses, Lilly could lose a key demand driver.

3. **Manufacturing bottlenecks**: The company is building two new plants in Texas and Virginia, but they won’t open until 2028 [7]. Until then, supply constraints could cap growth.

4. **Innovation Day (Dec. 7)**: Lilly’s annual R&D showcase could reveal whether its non-obesity pipeline can ever catch up to the GLP-1 cash tsunami [8].